IBRXImmunityBio, Inc.

$8B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$339,000-22.2% YoY

Gross Profit

$339,000100.0% margin

Operating Income

-$86M-25341.0% margin

Net Income

-$88M-26043.7% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+143.9%

Cash Flow

Operating Cash Flow

-$70M

Free Cash Flow

-$78M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$246M

Total Liabilities

$405M

Stockholders' Equity

-$158M

Cash & Equivalents

$84M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$339,000	$436,000	-22.2%
Gross Profit	$339,000	$436,000	-22.2%
Operating Income	-$86M	-$51M	-68.7%
Net Income	-$88M	-$51M	-71.6%

IBRX Q2 2021 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena